| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Revenue | $317.0M | -0.6% |
| Cost of Revenue | $81.0M | +7.3% |
| Gross Profit | $236.1M | -3.1% |
| R&D Expense | $87.9M | +3.4% |
| SG&A Expense | $55.9M | +13.1% |
| Operating Income | -$59.3M | -8.0% |
| Pre-tax Income | -$80.7M | -8.6% |
| Income Tax | $1.2M | -3.7% |
| Net Income | -$81.9M |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $45.3M | -25.7% |
| Accounts Receivable | $71.5M | +6.5% |
| Current Assets | $141.7M | -7.8% |
| Total Assets | $214.3M | -5.0% |
| Current Liabilities | $254.9M | +7.2% |
| Long-term Debt | $117.7M | +3.6% |
| Total Liabilities | $391.6M | +3.3% |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$9.1M | -450.4% |
| Capital Expenditures | $9.4M | -19.5% |
| Investing Cash Flow | -$9.4M | +19.7% |
| Financing Cash Flow | $3.4M | -2.3% |
| Free Cash Flow | -$18.5M | -102.1% |
| -8.4% |
| EPS (Basic) | -$2.13 | -1.4% |
| EPS (Diluted) | -$2.13 | -1.4% |
| Stockholders' Equity |
| -$177.2M |
| -15.4% |